肿瘤细胞治疗研究
英文原题：CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
嵌合抗原受体 (CAR)-NK 细胞治疗具有副作用发生率低和成本低的优势。
嵌合抗原受体（CAR）NK 细胞疗法具有副作用发生率低、成本低等优势。然而，由于抗肿瘤效应有限、增殖能力不足，其临床结局尚不理想。近期 CAR-NK 疗法在 NK 细胞工程改造、靶点设计及与其他药物联用方面取得进展，用于治疗复发或难治性血液系统恶性肿瘤，尤其是急性髓系白血病和多发性骨髓瘤。本文总结 2022 年 ASH 年会上报告的通用 CAR-NK 细胞疗法临床前及临床最新进展。
Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting.
MEMBER ACCOUNT
登录成功会直接打开下一页。
